- The European Medicines Agency's advisory group CHMP has issued a positive opinion recommending approval of ViiV Healthcare's Rukobia (fostemsavir) 600 mg extended-release tablets for the treatment of HIV-1 infection.
- Final marketing authorization from the European Commission is anticipated in the coming months. Fostemsavir was approved by the US FDA on July 2, 2020 and further regulatory applications have been submitted worldwide.
- ViiV Healthcare is the HIV-focused joint venture between GlaxoSmithKline (NYSE:GSK), Pfizer (NYSE:PFE) and Shionogi (OTCPK:SGIOY).
- https://seekingalpha.com/news/3643646-european-advisory-group-backs-viivs-rukobia-in-hivminus-1-infection
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.